Inhalation CDMO Market Size, Trends and Insights By Product (API, Inhalation Platform), By Services (Formulation Development, Device Development and Manufacturing, Clinical Manufacturing, Scale-up and Tech Transfer, Quality Control and Quality Assurance, Technology and Innovation, Regulatory Assistance, Analytical Services), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033
Report Snapshot
| Study Period: | 2024-2033 |
| Fastest Growing Market: | Asia-Pacific |
| Largest Market: | Europe |
Major Players
- Recipharm AB
- AptarGroup Inc.
- Hovione
- Vectura Group Ltd
- Nemera
- Kindeva
- Others
Reports Description
Global Inhalation CDMO Market was valued at USD 8.5 Billion in 2024 and is expected to reach USD 12.6 Billion by 2033, at a CAGR of 5.9% during the forecast period 2024 – 2033.
Businesses that specialise in offering complete development and manufacturing assistance for pharmaceutical products based on inhalation are known as inhalation CDMO (Contract Development and Manufacturing Organisation) services providers.
Inhalation CDMO Market: Growth Factors
Innovations in inhalation drug delivery systems
Innovations in inhalation drug delivery systems have fuelled the growth of the inhalation Contract Development and Manufacturing Organization (CDMO) market by enhancing efficacy, safety, and patient convenience.
Metered-dose inhalers (MDIs), nebulizers, and dry powder inhalers (DPIs) are examples of advanced technology that allow more accurate dosage, better drug dispersion, and tailored administration to the respiratory system.
These advancements tackle issues like irregular medication administration and non-adherence by patients, increasing the need for the specialized knowledge and production capacities provided by CDMOs.
In addition, the prevalence of respiratory conditions such as COVID-19, asthma, and chronic obstructive pulmonary disease (COPD) has prompted pharmaceutical firms to create innovative inhalation treatments, resulting in partnerships with CDMOs for formulation research, commercial manufacturing, and scale-up.
With their knowledge in inhalation drug delivery systems, CDMOs may offer comprehensive services, from formulation optimisation to regulatory compliance, which can shorten timeframes for product development and save costs for pharmaceutical firms.
Consequently, the market for inhalation CDMOs is expanding rapidly due to the ongoing advancements in inhalation drug delivery technologies as well as the rising need for efficient respiratory therapies.
Surging demand for efficient respiratory care
The market for inhalation Contract Development and Manufacturing Organisations (CDMOs) has grown as a result of the increasing need for effective respiratory treatment. Asthma, cystic fibrosis, and chronic obstructive pulmonary disease (COPD) are among the respiratory disorders that are becoming more common.
As a result, there is a rising demand for novel inhalation treatments with enhanced efficacy, safety, and patient compliance. By providing specialised knowledge in the development and production of inhalation products, such as metered dosage inhalers (MDIs), dry powder inhalers (DPIs), and nebulizers, inhalation CDMOs play a critical role in addressing this need.
These CDMOs give pharmaceutical businesses the resources and infrastructure needed to create and produce inhalation treatments economically and efficiently. The COVID-19 pandemic has also highlighted the significance of respiratory health, which has increased demand for inhalation treatments for respiratory infections and their comorbidities.
Consequently, as pharmaceutical firms look to capitalise on the growing prospects in the respiratory care industry and meet the changing demands of patients globally, the inhalation CDMO market is growing significantly.
Inhalation CDMO Market: Restraints
High cost
One of the main obstacles to entrance and market expansion in the inhalation drug development and manufacturing (CDMO) services is their high cost. When compared to standard oral pharmaceuticals, inhalation drug delivery systems naturally incur greater development and production costs due to their specialised technology and expertise.
The difficulties in creating medications that are inhaled, guaranteeing accurate dosage, and attaining reliable distribution all add to the high expenses. The cost burden is further increased by the strict regulatory requirements set by health authorities, especially for inhaled goods because of safety, effectiveness, and quality concerns.
These regulations call for substantial testing, documentation, and compliance efforts. Pharmaceutical businesses may therefore find it difficult to finance the initial outlay necessary for inhalation CDMO services, particularly smaller ones with little funding.Pharmaceutical businesses may therefore find it difficult to finance the initial outlay necessary for inhalation CDMO services, particularly smaller ones with little funding.
The high price may discourage innovation and restrict market access, impeding the creation of novel inhalable treatments and perhaps limiting patient access to necessary respiratory drugs.
Inhalation CDMO Market: Opportunities
Adoption of newly launched nebulizers
The market for inhalation Contract Development and Manufacturing Organisations (CDMOs) may be considerably boosted by the use of recently released nebulizers, which will increase demand for specialised skills and knowledge in the creation and production of inhalation treatments.
The advent of novel nebulizer technologies has presented opportunities for pharmaceutical firms, but these companies frequently lack the internal resources and expertise needed for effective product development and manufacture.
As a result, they look to inhalation CDMOs to take advantage of their proficiency in regulatory compliance, device optimisation, and formulation development. Inhalation CDMOs are well-positioned to provide customised solutions, such as formulation design, production, scale-up, and packaging services, in response to the growing demand for these recently introduced nebulizers.
This will propel market expansion. Furthermore, pharmaceutical businesses can receive assistance from inhalation CDMOs in managing the intricate regulatory requirements related to inhalation medicines. This mutually beneficial link between the use of inhalation CDMOs and nebulizers highlights the critical role that CDMOs play in fostering pharmaceutical innovation and commercial expansion in the inhalation treatment industry.
Inhalation CDMO Market: Segmentation Analysis
Global Inhalation CDMO market is segmented by product, services, and region. Based on product, the market is classified into API and inhalation platform. API dominated market in 2023 with market share of 46.1% and is expected to keep its dominance during the forecast period 2024-2033.
The essential elements of inhalation drugs are known as APIs (Active Pharmaceutical Ingredients), which substantially propel the Contract Development and Manufacturing Organisation (CDMO) industry. APIs are essential to the development of inhalation products because they control the safety and effectiveness of drugs breathed.
Comprehensive services for inhalation medication development and manufacture, from formulation research to commercial-scale production, are the area of expertise for CDMOs. Their proficiency with API handling guarantees the creation of inhalation solutions that satisfy legal requirements and provide the best possible therapeutic results.
Additionally, by using their infrastructure, experience, and economies of scale in API production, CDMOs provide affordable solutions. Due to this, the development of inhalation drugs may be outsourced by pharmaceutical corporations, which eliminates the need for large upfront investments in infrastructure and knowledge.
Based on services, the market is classified into formulation development, device development and manufacturing, clinical manufacturing, scale-up and tech transfer, quality control and quality assurance, technology and innovation, regulatory assistance and analytical services.
Formulation development dominated market in 2023 with market share of 24.5% and is expected to keep its dominance during the forecast period 2024-2033. Formulation development plays a pivotal role in driving the inhalation Contract Development and Manufacturing Organization (CDMO) market owing to its critical contribution to the creation of effective and safe inhalation products.
The need for specialized knowledge in formulation creation has increased as pharmaceutical companies concentrate more on creating inhalation treatments for respiratory conditions such as cystic fibrosis, asthma, and chronic obstructive pulmonary disease (COPD).
Pharmaceutical businesses may benefit from the experience, resources, and adherence to regulations that inhalation CDMOs offer, as they offer end-to-end services from formulation research at the early stages to commercial manufacture.
These services are crucial in helping companies traverse the complicated landscape of inhalation product development. The creation of inhalation medicines with increased effectiveness, patient compliance, and safety profiles is made possible by CDMOs through the use of creative formulation tactics such particle engineering, drug delivery system optimisation, and enhanced stability profiles.
Additionally, the flexibility and scalability that CDMOs provide in their production processes enable pharmaceutical firms to effectively move inhalation medicines from development to market, which in turn propels the inhalation CDMO market’s growth.
All things considered, the foundation of inhalation product development is formulation development, which also drives demand for specialised CDMO services and promotes innovation in respiratory medicine.
Report Scope
| Feature of the Report | Details |
| Market Size in 2024 | USD 8.5 Billion |
| Projected Market Size in 2033 | USD 12.6 Billion |
| Market Size in 2023 | USD 8.1 Billion |
| CAGR Growth Rate | 5.9% CAGR |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Key Segment | By Product, Services and Region |
| Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
| Regional Scope | North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America |
| Buying Options | Request tailored purchasing options to fulfil your requirements for research. |
Inhalation CDMO Market: Regional Analysis
By region, Inhalation CDMO market is segmented into North America, Europe, Asia-Pacific, Latin America, Middle East & Africa. The North America dominated the global Inhalation CDMO market in 2023 with market share of 42.2% and is expected to keep its dominance during the forecast period 2024-2033.
North America plays a pivotal role in driving the Contract Development and Manufacturing Organization (CDMO) market for inhalation products due to several key factors. The area has a thriving biotechnology and pharmaceutical sector that has a special emphasis on respiratory medicines, such as treatments for chronic obstructive pulmonary disease (COPD) and asthma.
Furthermore, a sizable amount of the world’s pharmaceutical industry is concentrated in North America, which presents several prospects for CDMOs that specialize in the research and production of inhalation products.
Moreover, pharmaceutical firms are motivated to contract with specialised CDMOs for the development and production of inhalation products due to strict regulatory requirements and the necessity of adhering to Good Production Practices (GMP).
In addition, the area enjoys the advantages of a highly trained labor force, cutting-edge facilities, and technological know-how, which promote creativity and effectiveness in the creation of inhalation products. North America’s market dominance in inhalation CDMO services is sustained by its thriving pharmaceutical industry, regulatory environment, and technological capabilities.
Inhalation CDMO Market: Recent Developments
- In March 2023, Stevanato and Recipharm collaborated to improve soft mist inhalers.
- In December 2022, Recipharm announced the extension of commercial manufacturing facilities to support RedHill Biopharma’s Talicia® to 2026.
- In September 2022, Stevanato Group and Gerresheimer AG collaborated on developing an innovative readily available vial platform for the pharmaceutical industry.
List of the prominent players in the Inhalation CDMO Market:
- Recipharm AB
- AptarGroup Inc.
- Hovione
- Vectura Group Ltd
- Nemera
- Kindeva
- H&T Presspart
- Sanner GmbH
- Stevanato Group
- Medspray
- ICONOVO AB
- Lonza
- Gerresheimer AG
- Catalent
- Thermo Fisher Scientific Inc.
- Lubrizol Life Science
- Enteris BioPharma
- Cambrex Corporation
- INKE
- Piramal Pharma Limited
- Lupin
- Others
These key players are adopting various growth strategies such as mergers & acquisitions, joint ventures, expansion, strategic alliances, new product launches, etc. to enhance their business operations and revenues.
The Inhalation CDMO Market is segmented as follows:
By Service:
- Formulation Development
- Device Development and Manufacturing
- Clinical Manufacturing
- Scale-up and Tech Transfer
- Quality Control and Quality Assurance
- Technology and Innovation
- Regulatory Assistance
- Analytical Services
By Product:
- API
- API Substrate
- Large Molecule
- Small Molecule
- Inhalation Platform
- Dry Powder Inhaler (DPIs)
- Metered Dose Inhaler (MDIs)
- Soft Mist Inhaler
By Company Size:
- Large
- Medium
- Small
By Scale of Operation:
- Preclinical
- Clinical
- Commercial
Regional Coverage:
North America
- U.S.
- Canada
- Mexico
- Rest of North America
Europe
- Germany
- France
- U.K.
- Russia
- Italy
- Spain
- Netherlands
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Taiwan
- Rest of Asia Pacific
The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of the Middle East & Africa
Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
- Chapter 1. Preface
- 1.1 Report Description and Scope
- 1.2 Research scope
- 1.3 Research methodology
- 1.3.1 Market Research Type
- 1.3.2 Market Research Methodology
- Chapter 2. Executive Summary
- 2.1 Global Inhalation CDMO Market, (2024 – 2033) (USD Billion)
- 2.2 Global Inhalation CDMO Market: snapshot
- Chapter 3. Global Inhalation CDMO Market – Industry Analysis
- 3.1 Inhalation CDMO Market: Market Dynamics
- 3.2 Market Drivers
- 3.2.1 Innovations in inhalation drug delivery systems
- 3.2.2 Surging demand for efficient respiratory care
- 3.3 Market Restraints
- 3.4 Market Opportunities
- 3.5 Market Challenges
- 3.6 Porter’s Five Forces Analysis
- 3.7 Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Product
- 3.7.2 Market Attractiveness Analysis By Services
- Chapter 4. Global Inhalation CDMO Market- Competitive Landscape
- 4.1 Company market share analysis
- 4.1.1 Global Inhalation CDMO Market: company market share, 2023
- 4.2 Strategic development
- 4.2.1 Acquisitions & mergers
- 4.2.2 New Product launches
- 4.2.3 Agreements, partnerships, collaboration, and joint ventures
- 4.2.4 Research and development and Regional expansion
- 4.3 Price trend analysis
- 4.1 Company market share analysis
- Chapter 5. Global Inhalation CDMO Market – Product Analysis
- 5.1 Global Inhalation CDMO Market Overview: By Product
- 5.1.1 Global Inhalation CDMO Market Share, By Product, 2023 and 2033
- 5.2 API
- 5.2.1 Global Inhalation CDMO Market by API, 2024 – 2033 (USD Billion)
- 5.3 Inhalation Platform
- 5.3.1 Global Inhalation CDMO Market by Inhalation Platform, 2024 – 2033 (USD Billion)
- 5.1 Global Inhalation CDMO Market Overview: By Product
- Chapter 6. Global Inhalation CDMO Market – Services Analysis
- 6.1 Global Inhalation CDMO Market Overview: By Services
- 6.1.1 Global Inhalation CDMO Market Share, By Services, 2023 and 2033
- 6.2 Formulation Development
- 6.2.1 Global Inhalation CDMO Market by Formulation Development, 2024 – 2033 (USD Billion)
- 6.3 Device Development and Manufacturing
- 6.3.1 Global Inhalation CDMO Market by Device Development and Manufacturing, 2024 – 2033 (USD Billion)
- 6.4 Clinical Manufacturing
- 6.4.1 Global Inhalation CDMO Market by Clinical Manufacturing, 2024 – 2033 (USD Billion)
- 6.5 Scale-up and Tech Transfer
- 6.5.1 Global Inhalation CDMO Market by Scale-up and Tech Transfer, 2024 – 2033 (USD Billion)
- 6.6 Quality Control and Quality Assurance
- 6.6.1 Global Inhalation CDMO Market by Quality Control and Quality Assurance, 2024 – 2033 (USD Billion)
- 6.7 Technology and Innovation
- 6.7.1 Global Inhalation CDMO Market by Technology and Innovation, 2024 – 2033 (USD Billion)
- 6.8 Regulatory Assistance
- 6.8.1 Global Inhalation CDMO Market by Regulatory Assistance, 2024 – 2033 (USD Billion)
- 6.9 Analytical Services
- 6.9.1 Global Inhalation CDMO Market by Analytical Services, 2024 – 2033 (USD Billion)
- 6.1 Global Inhalation CDMO Market Overview: By Services
- Chapter 7. Inhalation CDMO Market – Regional Analysis
- 7.1 Global Inhalation CDMO Market Regional Overview
- 7.2 Global Inhalation CDMO Market Share, by Region, 2023 & 2033 (USD Billion)
- 7.3. North America
- 7.3.1 North America Inhalation CDMO Market, 2024 – 2033 (USD Billion)
- 7.3.1.1 North America Inhalation CDMO Market, by Country, 2024 – 2033 (USD Billion)
- 7.3.1 North America Inhalation CDMO Market, 2024 – 2033 (USD Billion)
- 7.4 North America Inhalation CDMO Market, by Product, 2024 – 2033
- 7.4.1 North America Inhalation CDMO Market, by Product, 2024 – 2033 (USD Billion)
- 7.5 North America Inhalation CDMO Market, by Services, 2024 – 2033
- 7.5.1 North America Inhalation CDMO Market, by Services, 2024 – 2033 (USD Billion)
- 7.6. Europe
- 7.6.1 Europe Inhalation CDMO Market, 2024 – 2033 (USD Billion)
- 7.6.1.1 Europe Inhalation CDMO Market, by Country, 2024 – 2033 (USD Billion)
- 7.6.1 Europe Inhalation CDMO Market, 2024 – 2033 (USD Billion)
- 7.7 Europe Inhalation CDMO Market, by Product, 2024 – 2033
- 7.7.1 Europe Inhalation CDMO Market, by Product, 2024 – 2033 (USD Billion)
- 7.8 Europe Inhalation CDMO Market, by Services, 2024 – 2033
- 7.8.1 Europe Inhalation CDMO Market, by Services, 2024 – 2033 (USD Billion)
- 7.9. Asia Pacific
- 7.9.1 Asia Pacific Inhalation CDMO Market, 2024 – 2033 (USD Billion)
- 7.9.1.1 Asia Pacific Inhalation CDMO Market, by Country, 2024 – 2033 (USD Billion)
- 7.9.1 Asia Pacific Inhalation CDMO Market, 2024 – 2033 (USD Billion)
- 7.10 Asia Pacific Inhalation CDMO Market, by Product, 2024 – 2033
- 7.10.1 Asia Pacific Inhalation CDMO Market, by Product, 2024 – 2033 (USD Billion)
- 7.11 Asia Pacific Inhalation CDMO Market, by Services, 2024 – 2033
- 7.11.1 Asia Pacific Inhalation CDMO Market, by Services, 2024 – 2033 (USD Billion)
- 7.12. Latin America
- 7.12.1 Latin America Inhalation CDMO Market, 2024 – 2033 (USD Billion)
- 7.12.1.1 Latin America Inhalation CDMO Market, by Country, 2024 – 2033 (USD Billion)
- 7.12.1 Latin America Inhalation CDMO Market, 2024 – 2033 (USD Billion)
- 7.13 Latin America Inhalation CDMO Market, by Product, 2024 – 2033
- 7.13.1 Latin America Inhalation CDMO Market, by Product, 2024 – 2033 (USD Billion)
- 7.14 Latin America Inhalation CDMO Market, by Services, 2024 – 2033
- 7.14.1 Latin America Inhalation CDMO Market, by Services, 2024 – 2033 (USD Billion)
- 7.15. The Middle-East and Africa
- 7.15.1 The Middle-East and Africa Inhalation CDMO Market, 2024 – 2033 (USD Billion)
- 7.15.1.1 The Middle-East and Africa Inhalation CDMO Market, by Country, 2024 – 2033 (USD Billion)
- 7.15.1 The Middle-East and Africa Inhalation CDMO Market, 2024 – 2033 (USD Billion)
- 7.16 The Middle-East and Africa Inhalation CDMO Market, by Product, 2024 – 2033
- 7.16.1 The Middle-East and Africa Inhalation CDMO Market, by Product, 2024 – 2033 (USD Billion)
- 7.17 The Middle-East and Africa Inhalation CDMO Market, by Services, 2024 – 2033
- 7.17.1 The Middle-East and Africa Inhalation CDMO Market, by Services, 2024 – 2033 (USD Billion)
- Chapter 8. Company Profiles
- 8.1 Recipharm AB
- 8.1.1 Overview
- 8.1.2 Financials
- 8.1.3 Product Portfolio
- 8.1.4 Business Strategy
- 8.1.5 Recent Developments
- 8.2 AptarGroup Inc.
- 8.2.1 Overview
- 8.2.2 Financials
- 8.2.3 Product Portfolio
- 8.2.4 Business Strategy
- 8.2.5 Recent Developments
- 8.3 Hovione
- 8.3.1 Overview
- 8.3.2 Financials
- 8.3.3 Product Portfolio
- 8.3.4 Business Strategy
- 8.3.5 Recent Developments
- 8.4 Vectura Group Ltd
- 8.4.1 Overview
- 8.4.2 Financials
- 8.4.3 Product Portfolio
- 8.4.4 Business Strategy
- 8.4.5 Recent Developments
- 8.5 Nemera
- 8.5.1 Overview
- 8.5.2 Financials
- 8.5.3 Product Portfolio
- 8.5.4 Business Strategy
- 8.5.5 Recent Developments
- 8.6 Kindeva
- 8.6.1 Overview
- 8.6.2 Financials
- 8.6.3 Product Portfolio
- 8.6.4 Business Strategy
- 8.6.5 Recent Developments
- 8.7 H&T Presspart
- 8.7.1 Overview
- 8.7.2 Financials
- 8.7.3 Product Portfolio
- 8.7.4 Business Strategy
- 8.7.5 Recent Developments
- 8.8 Sanner GmbH
- 8.8.1 Overview
- 8.8.2 Financials
- 8.8.3 Product Portfolio
- 8.8.4 Business Strategy
- 8.8.5 Recent Developments
- 8.9 Stevanato Group
- 8.9.1 Overview
- 8.9.2 Financials
- 8.9.3 Product Portfolio
- 8.9.4 Business Strategy
- 8.9.5 Recent Developments
- 8.10 Medspray
- 8.10.1 Overview
- 8.10.2 Financials
- 8.10.3 Product Portfolio
- 8.10.4 Business Strategy
- 8.10.5 Recent Developments
- 8.11 ICONOVO AB
- 8.11.1 Overview
- 8.11.2 Financials
- 8.11.3 Product Portfolio
- 8.11.4 Business Strategy
- 8.11.5 Recent Developments
- 8.12 Lonza
- 8.12.1 Overview
- 8.12.2 Financials
- 8.12.3 Product Portfolio
- 8.12.4 Business Strategy
- 8.12.5 Recent Developments
- 8.13 Gerresheimer AG
- 8.13.1 Overview
- 8.13.2 Financials
- 8.13.3 Product Portfolio
- 8.13.4 Business Strategy
- 8.13.5 Recent Developments
- 8.14 Catalent
- 8.14.1 Overview
- 8.14.2 Financials
- 8.14.3 Product Portfolio
- 8.14.4 Business Strategy
- 8.14.5 Recent Developments
- 8.15 Thermo Fisher Scientific Inc.
- 8.15.1 Overview
- 8.15.2 Financials
- 8.15.3 Product Portfolio
- 8.15.4 Business Strategy
- 8.15.5 Recent Developments
- 8.16 Lubrizol Life Science
- 8.16.1 Overview
- 8.16.2 Financials
- 8.16.3 Product Portfolio
- 8.16.4 Business Strategy
- 8.16.5 Recent Developments
- 8.17 Enteris BioPharma
- 8.17.1 Overview
- 8.17.2 Financials
- 8.17.3 Product Portfolio
- 8.17.4 Business Strategy
- 8.17.5 Recent Developments
- 8.18 Cambrex Corporation
- 8.18.1 Overview
- 8.18.2 Financials
- 8.18.3 Product Portfolio
- 8.18.4 Business Strategy
- 8.18.5 Recent Developments
- 8.19 INKE
- 8.19.1 Overview
- 8.19.2 Financials
- 8.19.3 Product Portfolio
- 8.19.4 Business Strategy
- 8.19.5 Recent Developments
- 8.20 Piramal Pharma Limited
- 8.20.1 Overview
- 8.20.2 Financials
- 8.20.3 Product Portfolio
- 8.20.4 Business Strategy
- 8.20.5 Recent Developments
- 8.21 Lupin
- 8.21.1 Overview
- 8.21.2 Financials
- 8.21.3 Product Portfolio
- 8.21.4 Business Strategy
- 8.21.5 Recent Developments
- 8.22 Others.
- 8.22.1 Overview
- 8.22.2 Financials
- 8.22.3 Product Portfolio
- 8.22.4 Business Strategy
- 8.22.5 Recent Developments
- 8.1 Recipharm AB
List Of Figures
Figures No 1 to 24
List Of Tables
Tables No 1 to 52
Report Methodology
In order to get the most precise estimates and forecasts possible, Custom Market Insights applies a detailed and adaptive research methodology centered on reducing deviations. For segregating and assessing quantitative aspects of the market, the company uses a combination of top-down and bottom-up approaches. Furthermore, data triangulation, which examines the market from three different aspects, is a recurring theme in all of our research reports. The following are critical components of the methodology used in all of our studies:
Preliminary Data Mining
On a broad scale, raw market information is retrieved and compiled. Data is constantly screened to make sure that only substantiated and verified sources are taken into account. Furthermore, data is mined from a plethora of reports in our archive and also a number of reputed & reliable paid databases. To gain a detailed understanding of the business, it is necessary to know the entire product life cycle and to facilitate this, we gather data from different suppliers, distributors, and buyers.
Surveys, technological conferences, and trade magazines are used to identify technical issues and trends. Technical data is also gathered from the standpoint of intellectual property, with a focus on freedom of movement and white space. The dynamics of the industry in terms of drivers, restraints, and valuation trends are also gathered. As a result, the content created contains a diverse range of original data, which is then cross-validated and verified with published sources.
Statistical Model
Simulation models are used to generate our business estimates and forecasts. For each study, a one-of-a-kind model is created. Data gathered for market dynamics, the digital landscape, development services, and valuation patterns are fed into the prototype and analyzed concurrently. These factors are compared, and their effect over the projected timeline is quantified using correlation, regression, and statistical modeling. Market forecasting is accomplished through the use of a combination of economic techniques, technical analysis, industry experience, and domain knowledge.
Short-term forecasting is typically done with econometric models, while long-term forecasting is done with technological market models. These are based on a synthesis of the technological environment, legal frameworks, economic outlook, and business regulations. Bottom-up market evaluation is favored, with crucial regional markets reviewed as distinct entities and data integration to acquire worldwide estimates. This is essential for gaining a thorough knowledge of the industry and ensuring that errors are kept to a minimum.
Some of the variables taken into account for forecasting are as follows:
• Industry drivers and constraints, as well as their current and projected impact
• The raw material case, as well as supply-versus-price trends
• Current volume and projected volume growth through 2033
We allocate weights to these variables and use weighted average analysis to determine the estimated market growth rate.
Primary Validation
This is the final step in our report’s estimating and forecasting process. Extensive primary interviews are carried out, both in-person and over the phone, to validate our findings and the assumptions that led to them.
Leading companies from across the supply chain, including suppliers, technology companies, subject matter experts, and buyers, use techniques like interviewing to ensure a comprehensive and non-biased overview of the business. These interviews are conducted all over the world, with the help of local staff and translators, to overcome language barriers.
Primary interviews not only aid with data validation, but also offer additional important insight into the industry, existing business scenario, and future projections, thereby improving the quality of our reports.
All of our estimates and forecasts are validated through extensive research work with key industry participants (KIPs), which typically include:
• Market leaders
• Suppliers of raw materials
• Suppliers of raw materials
• Buyers.
The following are the primary research objectives:
• To ensure the accuracy and acceptability of our data.
• Gaining an understanding of the current market and future projections.
Data Collection Matrix
| Perspective | Primary research | Secondary research |
| Supply-side |
|
|
| Demand-side |
|
|
Market Analysis Matrix
| Qualitative analysis | Quantitative analysis |
|
|
Prominent Player
- Recipharm AB
- AptarGroup Inc.
- Hovione
- Vectura Group Ltd
- Nemera
- Kindeva
- H&T Presspart
- Sanner GmbH
- Stevanato Group
- Medspray
- ICONOVO AB
- Lonza
- Gerresheimer AG
- Catalent
- Thermo Fisher Scientific Inc.
- Lubrizol Life Science
- Enteris BioPharma
- Cambrex Corporation
- INKE
- Piramal Pharma Limited
- Lupin
- Others
FAQs
The restraints of the Inhalation CDMO market is high cost.
The major driver for the Inhalation CDMO market is innovations in inhalation drug delivery systems and surging demand for efficient respiratory care.
The “API” category dominated the market in 2023.
The key players in the market are Recipharm AB, AptarGroup Inc., Hovione, Vectura Group Ltd, Nemera, Kindeva, H&T Presspart, Sanner GmbH, Stevanato Group, Medspray, ICONOVO AB, Lonza, Gerresheimer AG, Catalent, Thermo Fisher Scientific Inc., Lubrizol Life Science, Enteris BioPharma, Cambrex Corporation, INKE, Piramal Pharma Limited, Lupin, Others.
“North America” had the largest share in the Inhalation CDMO Market.
The global market is projected to grow at a CAGR of 5.9% during the forecast period, 2024-2033.
The Inhalation CDMO Market size was valued at USD 8.5 Billion in 2024.